2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Carbonic Anhydrase

Carbonic Anhydrase

Anhydrase

Carbonate dehydratase

Carbonic Anhydrase

Related Products

PDF 0.73 MB

Carbonic anhydrase (CA) is a zinc-containing enzyme that catalyzes the reversible hydration of carbon dioxide: CO2 + H2O ⇋ HCO3- + H+. Eight genetically distinct carbonic anhydrase enzyme families (α-, β-, γ- δ-, ζ-, η-, θ- and ι- CAs) were described to date. Carbonic anhydrases are involved in numerous physiological and pathological processes. Many of them are important therapeutic targets with the potential to be inhibited to treat a range of disorders including oedema, glaucoma, obesity, cancer, epilepsy, and osteoporosis.

The carbonic anhydrase reaction is involved in many physiological and pathological processes, including respiration and transport of CO2 and bicarbonate between metabolizing tissues and lungs; pH and CO2 homeostasis; electrolyte secretion in various tissues and organs; biosynthetic reactions (such as gluconeogenesis, lipogenesis, and ureagenesis); bone resorption; calcification; and tumorigenicity. α-CAs are Zn2+ metalloproteins expressed in animals, vertebrates, prokaryotes, fungi, algae, protozoa, and plants. Sixteen mammalian α-CA isoforms are known to be involved in many diseases such as glaucoma, edema, epilepsy, obesity, hypoxic tumors, neuropathic pain, arthritis, neurodegeneration, etc.

Carbonic Anhydrase Isoform Specific Products:

Carbonic Anhydrase Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-150695
    hCAIX/XII-IN-5
    		Inhibitor
    hCAIX/XII-IN-5 (Coumarin 9a) a carbonic anhydrase (CA) inhibitor, and exhibits excellent hCA IX/XII selectivity (Ki=93.9 and 85.7 nM, respectively) over hCA I and hCA II. hCAIX/XII-IN-5 shows anti-proliferative activities to cancer cells. hCAIX/XII-IN-5 can delay cell cycle and induce apoptosis.
    hCAIX/XII-IN-5
  • HY-168124
    Carbonic anhydrase inhibitor 26
    		Inhibitor
    Carbonic anhydrase inhibitor 26 (compund 6T) is a carbonic anhydrase II inhibitor with IC50 of 9.10 ± 0.26 μM.
    Carbonic anhydrase inhibitor 26
  • HY-155271
    hCAXII-IN-7
    		Inhibitor
    hCAXII-IN-7 (compound 6e) is a hCA XII inhibitor. hCAXII-IN-7 has BBB permeability. hCAXII-IN-7 induces 786-0, SF-539 and HS 578 T cells apoptotic.
    hCAXII-IN-7
  • HY-161174
    Carbonic anhydrase inhibitor 17
    		Inhibitor
    Carbonic anhydrase inhibitor 17 (compound 7c) ,pyridazine-tethered sulfonamide, is a carbonic anhydrase II inhibitor with IC50 of 0.63 nM.
    Carbonic anhydrase inhibitor 17
  • HY-150573
    CDK2-IN-12
    		Inhibitor
    CDK2-IN-12 (compound 10b) is a potent CDK2 inhibitor, with an IC50 of 11.6 μM. CDK2-IN-12 inhibits hCA (carbonic anhydrase) isoforms I, II, IX and XII, with KI values of 3534, 638.4, 44.3, and 48.8 nM. CDK2-IN-12 shows anticancer activity.
    CDK2-IN-12
  • HY-155760
    hCA/VEGFR-2-IN-3
    		Inhibitor
    hCA/VEGFR-2-IN-3 (compound 8j) is an indolinonylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-3 inhibits VEGFR-2 (IC50=358 nM), has high binding activity to hCAs with Ki of 4.2 nM (hCA IX), 22.9 nM (hCA II), 25.1 nM (hCA I), 28.0 nM (hCA XII), respectively. hCA/VEGFR-2-IN-3 has antiproliferative activity against VEGFR-2 overexpressing breast cancer cells.
    hCA/VEGFR-2-IN-3
  • HY-161522
    α-Glucosidase-IN-63
    		Inhibitor
    α-Glucosidase-IN-63 (Compound 4d) is an inhibitor of α-Glucosidase (IC50=0.44 μM). α-Glucosidase-IN-63 inhibits hCA II with an activity of Ki= 7.0 nM. α-Glucosidase-IN-63 is orally effective..
    α-Glucosidase-IN-63
  • HY-120677
    AHR-15010
    		Inhibitor
    AHR-15010 is an oral active carbonic anhydrase inhibitor with the IC50 of 0.13 μM. AHR-15010 shows anti-arthritic activity and can be used for study of arthritis .
    AHR-15010
  • HY-156013
    CA inhibitor 2
    		Inhibitor
    CA inhibitor 2 (Compound 4H) is a carbonic anhydrase inhibitor (IC50: 0.033 μM).
    CA inhibitor 2
  • HY-147828
    hCAIX-IN-11
    		Inhibitor
    hCAIX-IN-11 (Compound 5d) is a selective carbonic anhydrase IX and XII inhibitor with Ki s of 32.7 and 623.5 nM for hCA IX and hCA XII, respectively.  hCA IX and hCA XII are transmembrane isoforms which have been characterized as biomarkers for several types of tumors. The hCA XII assists in maintenance of acid-base homoeostasis in normal as well as tumor cells.
    hCAIX-IN-11
  • HY-151472
    hCAIX/XII-IN-6
    		Inhibitor
    hCAIX/XII-IN-6 is an orally active carbonic anhydrase (CA) inhibitor. hCAIX/XII-IN-6 inhibits human CA isoforms hCA I, II, IV, IX, and XII with Ki values of 6697 nM, 2950 nM, 4093 nM, 4.1 nM and 7.7 nM, respectively. hCAIX/XII-IN-6 can be used for the research of rheumatoid arthritis (RA).
    hCAIX/XII-IN-6
  • HY-147663
    hCAIX-IN-6
    Compounds 6b and 14g showed significant inhibitory effect on tumor related subtype HCA IX with low nanomolar potency, while 6k was effective on HCA XII. Compounds 6b, 14g and 6k can be considered as the leading molecules for the development of future cancer therapeutic drugs based on new mechanisms of action.
    hCAIX-IN-6
  • HY-19213
    L-693612
    		Inhibitor
    L-693612 (Compd 1) is an orally active and topical carbonic anhydrase inhibitor.
    L-693612
  • HY-169163
    BChE-IN-36
    		Activator
    hBChE-IN-4 (compound 40) is a potent hCA activator and BChE inhibitor with KA values of 266, 76.9, 918, 893, 98.0 nM for hCA I, hCA II, hCA IV, hCA VB, hCA VII, IC50 values of 72.1, 4.2 nM for eeAChE, eqBChE, respectively. hBChE-IN-4 shows no cytotoxicity. hBChE-IN-4 shows potent procognitive effects. hBChE-IN-4 has the potential for the research of neurodegenerative diseases and other neuropsychiatric disorders.
    BChE-IN-36
  • HY-152141
    hCAII-IN-9
    		Inhibitor
    hCAII-IN-9 is a potent carbonic anhydrase inhibitor with IC50s of 1.18 μM (hCA II), 0.17 μM (hCA IX), and 2.99 μM (hCA XII), respectively. hCAII-IN-9 has no blood-brain barrier permeability.
    hCAII-IN-9
  • HY-146983
    hCAIX-IN-3
    		Inhibitor
    hCAII-IN-3 (compound 7e) is a potent and selective inhibitor of carbonic anhydrase (CA II/IX) with Kis of 124.2 and 30.5 nM, respectively. hCAII-IN-3 has the potential for the research of cancer diseases.
    hCAIX-IN-3
  • HY-150977
    β-Glucuronidase/hCAII-IN-2
    		Inhibitor
    β-Glucuronidase/hCAII-IN-2 (Compound 12e) is a potent β-glucuronidase and hCA II inhibitor with an IC50 of 670.7 μM and 21.77 μM, respectively.
    β-Glucuronidase/hCAII-IN-2
  • HY-150976
    β-Glucuronidase/hCAII-IN-1
    		Inhibitor
    β-Glucuronidase/hCAII-IN-2 (Compound 12e) is a potent β-glucuronidase and hCA II inhibitor with an IC50 of 440.1 μM and 4.91 μM, respectively.
    β-Glucuronidase/hCAII-IN-1
  • HY-126117
    (+)-Xylariamide A
    		Inhibitor
    (+)-Xylariamide A (compound 6b) is a mycobacterial and fungal carbonic anhydrase probe with inhibitory activity against pathogen β-carbonic anhydrases.
    (+)-Xylariamide A
  • HY-155694
    hCA/VEGFR-2-IN-1
    		Inhibitor
    hCA/VEGFR-2-IN-1 (compound 13a) is a potent dual Carbonic Anhydrase(CA) IX/XII with Ki values of 4.7 nM and 8.3 nM for hCA XII and hCA IX, respectively. hCA/VEGFR-2-IN-1 (compound 13a) is a potent VEGFR-2 inhibitor with IC50 values 26.3 nM. hCA/VEGFR-2-IN-1 has anticancer activity.
    hCA/VEGFR-2-IN-1
Cat. No. Product Name / Synonyms Species Source
Carbonic Anhydrase Isoform Comparison

CA

CA I

CA Ⅱ

CA IX

CA XII

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

Carbonic Anhydrase Inhibitors, Activators & Modulators
Product NameCACA ICA ⅡCA IXCA XIIPurity    
Acetazolamide   
CA IX
 99.89%
U-104   
CA IX
CA XII
99.95%
DPI-4452   
hCA IX, Kd: 0.25 nM
 98.27%
hCAVII/IX-IN-1   
hCA IX, Ki: 38.2 nM
 
Girentuximab   
CA IX
 99.90%
Methazolamide  
CA Ⅱ
  99.41%
Zonisamide  
CA Ⅱ
  99.85%
Acetazolamide sodium   
CA IX
 99.54%
Dorzolamide hydrochloride  
CA Ⅱ
  99.92%
Brinzolamide  
CA Ⅱ
  99.61%
CAIX Inhibitor S4   
CA IX
 99.04%
Benzolamide  
CA Ⅱ
  99.07%
Acetazolamide (Standard)   
CA IX
 99.69%
Furagin   
hCA IX, Ki: 260 nM
hCA XII, Ki: 57 nM
99.84%
2-Aminobenzenesulfonamide   
CA IX
 99.90%
Halazone  
CA Ⅱ
  
Fluorometholone acetate  
CA Ⅱ
  98.54%
Benzenesulphonamide  
CA Ⅱ
  99.51%
Carbonic anhydrase inhibitor 2  
CA Ⅱ
  98.40%
hCAIX-IN-18 
hCA I, IC50: 3.5 nM
hCA II, IC50: 9.4 nM
hCA IX, IC50: 43 nM
hCA XII, IC50: 8.2 nM
98.52%
Procodazole   
CA IX, IC50: 8.35 μM
 99.73%
EMAC10101d  
CA Ⅱ
  99.77%
Enpp/Carbonic anhydrase-IN-1  
CA Ⅱ, IC50: 0.88 μM
CA IX, IC50: 1.02 μM
 99.57%
hCAII-IN-8  
hCA II, IC50: 0.18 μM
  99.41%
hCAXII-IN-9 
hCA I, Ki: 7192.6 nM
hCA II, Ki: 188.6 nM
hCA IX, Ki: >100000 nM
hCA XII, Ki: 28 nM
Lasamide   
hCA IX, Ki: 2.67 nM
hCA XII, Ki: 7.54 nM
99.97%
hCAIX/XII-IN-5   
hCA IX, Ki: 93.9 nM
hCA XII, Ki: 85.7 nM
α-Glucosidase-IN-63  
hCA II, Ki: 7.0 nM
hCA IX, Ki: 64.1 nM
hCA XII, Ki: 19.9 nM
hCAIX/XII-IN-6  
hCA II, Ki: 2950 nM
hCA IX, Ki: 4.1 nM
hCA XII, Ki: 7.7 nM
hCAIX-IN-6    
CA XII
BChE-IN-36
hCA VB, KA: 893 nM
hCA I, KA: 266 nM
hCA II, KA: 76.9 nM
  
hCAII-IN-9  
hCA II, IC50: 1.18 μM
hCA IX, IC50: 0.17 μM
hCA XII, IC50: 2.99 μM
β-Glucuronidase/hCAII-IN-2  
hCA II, IC50: 21.77 μM
  
β-Glucuronidase/hCAII-IN-1  
hCA II, IC50: 4.91 μM
  
hCAXII-IN-1   
CA IX
 
hCAIX/XII-IN-11   
hCA IX, Ki: 0.7 μM
hCA XII, Ki: 0.7 μM
Carbonic anhydrase inhibitor 14 
hCA I, Ki: 1203 nM
hCA II, Ki: 99.7 nM
hCA IX, Ki: 9.4 nM
hCA XII, Ki: 27.7 nM
Carbonic anhydrase inhibitor 3  
CA Ⅱ
  
CA Ⅱ-IN-1  
hCA II, : 0.44 μM
  
CAIX/CAXII-IN-1  
CA Ⅱ
CA IX
CA XII
Brinzolamide hydrochloride  
hCA II, IC50: 3.2 nM
  
hCAIX-IN-24   
hCA IX, Ki: 32.1 nM
hCA XII, Ki: 8.1 nM
hCAIX-IN-19   
hCA IX, Ki: 6.2 nM
 
AChE/hCA I-IN-1 
hCA I, IC50: 283.3 nM
hCA II, IC50: 265.9 nM
  
hCAIX-IN-17  
CA Ⅱ
CA IX
CA XII
Carbonic anhydrase/AChE-IN-1 
hCA I, Ki: 24.42 nM
hCA II, Ki: 19.95 nM
  
hCAIX-IN-14   
hCA IX, Ki: 134.8 nM
 
Carbonic anhydrase inhibitor 10   
CA IX
 
hCA/VEGFR-2-IN-5   
hCA IX, IC50: 40 nM
hCA XII, IC50: 3.2 nM
COX-2-IN-30 
hCA I, Ki: 183.4 nM
hCA II, Ki: 81.4 nM
hCA IX, Ki: 38.4 nM
hCA XII, Ki: 21.6 nM
hCAI/II-IN-10 
hCA I, IC50: 4.32 nM
hCA II, IC50: 3.89 nM
  
hCAII-IN-5  
hCA II, IC50: 4.55 μM
  
hCAIX-IN-22    
hCA XII, Ki: 9.7 nM
hCAII-IN-6  
CA Ⅱ
  
AChE/CA I-IN-1 
hCA I, Ki: 0.53 μM
   
Enpp/Carbonic anhydrase-IN-2   
CA IX, IC50: 0.33 μM
CA XII, IC50: 0.68 μM
99.76%
CA IX-IN-2  
CA Ⅱ, IC50: 430 nM
CA IX, IC50: 5.6 nM
CA XII, IC50: 7.4 nM
hCA I-IN-4 
hCA I, Ki: 29.94 nM
hCA II, Ki: 17.72 nM
  
hCAII/IX-IN-1  
hCA II, Ki: 7.4 nM
hCA IX, Ki: 7 nM
 
DTP348   
CA IX, Ki: 8.3 nM
 
HCAIX-IN-2 
CA I, Ki: 2481 nM
hCA II, Ki: 456.2 nM
hCA IX, Ki: 24.6 nM
hCA XII, Ki: 45.3 nM
hA2A/hCA XII modulator 1  
CA Ⅱ
 
CA XII
hCA I-IN-3 
hCA I, IC50: 4.77 nM
hCA II, IC50: 9.66 nM
  
hCAII/XII-IN-1  
CA Ⅱ, Ki: 9.4 nM
 
hCA XII, Ki: 8.4 nM
VM4-037   
CA IX
 
GZ22-4  
CA Ⅱ, Kd: 200 nM
CA IX, Kd: 0.2 nM
CA XII, Kd: 80 nM
DPP IV/hCA II-IN-1 
CA I, Ki: 0.2615 μM
CA Ⅱ, IC50: 36.1 nM
hCA II, Ki: 0.0361 μM
hCA IX, Ki: 0.1328
 
CAII-IN-3  
bovine CA-II, IC50: 13.4 μM
  
Carbonic anhydrase inhibitor 12  
CA Ⅱ
  
hCAII-IN-10 
hCA I, IC50: 29.2 μM
hCA II, IC50: 14 nM
  
hCAII-IN-4  
hCA II, IC50: 7.78 μM
  
Carbonic anhydrase inhibitor 9  
CA Ⅱ
CA IX
 
hCAIX-IN-15   
hCA IX, Ki: 38.8 nM
 
CAIX/CAXII-IN-2   
hCA IX, Ki: 8.9 nM
hCA XII, Ki: 5.3 nM
CA IX/VEGFR-2-IN-2   
CA IX, Ki: 3.1 μM
 
hCAIX/XII-IN-8 
hCA I, Ki: 5269 nM
hCA II, Ki: 72.0 nM
hCA IX, Ki: 8.5 nM
hCA XII, Ki: 6.7 nM
hCAIX-IN-21 
hCA I, Ki: 13600 nM
hCA II, Ki: 3.5 nM
hCA IX, Ki: 5.2 nM
hCA XII, Ki: 12.6 nM
Methazolamide-d6  
CA Ⅱ
  
CA IX/VEGFR-2-IN-3  
CA Ⅱ, IC50: 41 nM
  
hCAIX-IN-10   
CA IX
 
hCAII-IN-3  
CA Ⅱ
CA IX
CA XII
hCAI/II-IN-8 
hCA I, IC50: 21.35 nM
hCA II, IC50: 7.12 nM
  
hCAIX-IN-23   
hCA IX, Ki: 10.4 nM
hCA XII, Ki: 8.5 nM
CA/MAO-B-IN-1
hCA VB, IC50: 8.8 nM
hCA VA, IC50: 9.6 nM
hCA I, IC50: 553.1 nM
hCA II, IC50: 41.1 nM
 
hCA XII, IC50: 196 nM
98.34%
hCAIX/XII-IN-9 
hCA I, Ki: 1658 nM
hCA II, Ki: 184.8 nM
hCA IX, Ki: 8.9 nM
hCA XII, Ki: 64.8 nM
ALP/Carbonic anhydrase-IN-1  
CA Ⅱ, IC50: 0.44 μM
CA IX, IC50: 1.61 μM
CA XII, IC50: 0.51 μM
99.90%
HCAIX-IN-1 
hCA I, Ki: 694.9 nM
hCA II, Ki: 126.6 nM
hCA IX, Ki: 3.3 nM
hCA XII, Ki: 9.8 nM
Dorzolamide (hydrochloride) (Standard)  
CA Ⅱ
  
Acetazolamide-13C2,d3   
CA IX
 
Carbonic anhydrase inhibitor 20 
hCA I, Ki: 47.6 nM ([1])
hCA II, Ki: 36.5 nM ([1])
hCA IX, Ki: 8.3 nM ([1])
hCA XII, Ki: 2.7 nM ([1])
hCAIX-IN-12   
CA IX
 
hCAIX/XII-IN-1   
CA IX
 
hCAIX/XII-IN-7 
hCA I, Ki: 503.7 nM
hCA II, Ki: 59 nM
hCA IX, Ki: 3.2 nM
hCA XII, Ki: 9.2 nM
CAIX/CAXII-IN-4  
CA Ⅱ, Ki: 3.035 μM
CA IX, Ki: 1.324 μM
CA XII, Ki: 0.435 μM
Phenylsulfamide  
hCA II, Kd: 45.50 μM
hCA II, Ki: 79.60 μM
  
hCAIX-IN-8   
CA IX
 
Dorzolamide-d5  
CA Ⅱ
  
L-662583  
hCA II, IC50: 0.7 nM
  
CA IX-IN-3   
CA IX, IC50: 0.48 nM
 
Carbonic anhydrase inhibitor 25 
hCA I
hCA II
  
hCAI/II-IN-7
bovine CA, Ki: 20.57 μM
hCA I, Ki: 23 nM
hCA II, Ki: 44 nM
  
hCAIX/XII-IN-14  
hCA II, Ki: 9.4 nM
hCA IX, Ki: 5.6 nM
hCA XII, Ki: 6.3 nM
Carbonic anhydrase inhibitor 19 
hCA I, IC50: 49.1 nM
hCA II, IC50: 9.4 nM
hCA IX, IC50: 4.7 nM
hCA XII, IC50: 6.7 nM